If lymph node involvement is tested in the patient going through neoadjuvant therapy who is a possible prospect for targeted axillary dissection (TAD), a marker needs to be inserted from the lymph node immediately after biopsy.In the current randomized managed demo, MRI inside the really dense breast screening team with destructive MG confirmed a a